Progressive multifocal leukoencephalopathy in rituximab-treated rheumatic diseases: a rare event.

Abstract

This report assesses the observed risk of PML in patients treated with the anti-CD20 monoclonal antibody rituximab in the regulatory authority-approved autoimmune indications rheumatoid arthritis (RA), granulomatosis with polyangiitis (GPA), and microscopic polyangiitis (MPA). This was a cumulative analysis of confirmed PML cases in patients receiving rituximab for RA or GPA/MPA from both spontaneous reports and clinical trial sources, as captured in the manufacturer global company safety and clinical databases. Overall reporting rates were calculated and patient case details were summarized. As of 17 November 2015, there were nine confirmed PML cases among patients who had received rituximab for RA and two for GPA. Corresponding estimated reporting rates were 2.56 per 100,000 patients with RA (estimated exposure ≈ 351,396 patients) and < 1 per 10,000 patients with GPA/MPA (estimated exposure 40,000-50,000 patients). In all cases, patients had ≥ 1 potential risk factor for PML independent of rituximab treatment. In the RA population, the estimated reporting rate of PML generally remained stable and low since 2009 despite increasing rituximab exposure. There was no pattern of latency from time of rituximab initiation to PML development and no association of PML with the number of rituximab courses. Global post-marketing safety and clinical trial data demonstrated that the occurrence of PML is very rare among rituximab-treated patients with RA or GPA/MPA and has remained stable over time.

• Authors: Joseph R Berger, Vineeta Malik, Stuart Lacey, Paul Brunetta, Patricia B Lehane
• Journal: Journal of neurovirology (J Neurovirol) Vol. 24 Issue 3 Pg. 323-331 (06 2018) ISSN: 1538-2443 [Electronic] United States
• PMID: 29508305 (Publication Type: Case Reports, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Immunologic Factors
• Rituximab

Topics

• Aged
• Arthritis, Rheumatoid (drug therapy, immunology, pathology)
• Databases, Factual
• Female
• Granulomatosis with Polyangiitis (drug therapy, immunology, pathology)
• Humans
• Immunologic Factors (administration & dosage, adverse effects)
• JC Virus (isolation & purification, pathogenicity)
• Leukoencephalopathy, Progressive Multifocal (chemically induced, diagnosis, epidemiology, virology)
• Male
• Microscopic Polyangiitis (drug therapy, immunology, pathology)
• Middle Aged
• Rituximab (administration & dosage, adverse effects)
• Switzerland
• United Kingdom
• United States
• Virus Activation (drug effects)